Benzyl 2-[[(2R)-2-[[2-(tert-Butoxycarbonylamino)acetyl]amino]-4-methyl-pentanoyl]amino]acetate, 98%, 500mg

1-(4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid, 95.0%, 2g

N,N-Diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, 95.0%, 5g

(2-Bromo-5-methylthiazol-4-yl)methanol, 97%, 50mg

FUSIDIC ACID, 95%, 100g

2,4,5-Trimethylthiazole, 95.0%, 100g

Sodium 1-amino-4-bromo-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate, 98%, 500g

2-((3,4-Dimethylphenyl)carbamoyl)cyclohexane-1-carboxylic acid, 97%, 1g

2-Amino-4-chloro-5-iodobenzoic acid, 97%, 1g

iScope IS.1158-PLPHi Biocular for phase contrast with Plan phase IOS objectives and Rackless cross stage (infinity - ergonomic tilting head)

N-HYDROXY-2,3-DIMETHYL-BENZAMIDINE, 95.0%, 250mg

1-[4-methoxy-3-(methoxymethyl)phenyl]ethan-1-one, 97%, 100mg

1-Methyl-4,5-dihydro-1H-imidazole-2-thiol, 95.0%, 100mg